Effects of Whole-Body Vibration Exercise on Serum IGF-1 in Fibromyalgia

Fibromyalgia Clinical Trial

Official title:

Effect of Acute and Chronic Whole-Body Vibration Exercise on Serum Insulin-Like Growth Factor-1 Levels in Women With Fibromyalgia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00650715
• Other study ID #: WBVIGF1FM
• Status: Completed
• Phase: N/A
• First received: March 31, 2008
• Last updated: March 31, 2008
• Start date: December 2004
• Est. completion date: January 2005

Study information

• Verified date: March 2008
• Source: Institut Nacional d'Educacio Fisica de Catalunya
• Contact: n/a
• Is FDA regulated: No
• Health authority: Spain: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The purpose of this study was to investigate the acute and chronic effect of whole-body vibration exercise on serum insulin-like growth factor-1 levels in women with fibromyalgia (FM). It was hypothesized that women with FM would exhibit an increase in IGF-1 following both acute and chronic WBV. Twenty-four women with FM were randomized into two groups: Vibration Group (VG) and Control Group (CG). The VG underwent a protocol with WBV exercise twice a week for a total of six weeks, whereas the CG performed the same protocol without vibratory stimulus. Both groups continued with their usual pharmacological treatment. Serum IGF-1 levels were determined using Enzyme-Linked Immunosorbent Assay (ELISA). To test the effect of chronic WBV, serum IGF-1 measurements were taken at baseline and at weeks 1,3, and 6 of intervention. To test the effect of acute WBV, within week 1, serum IGF-1 measurements were taken before and immediately following a session of WBV.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: January 2005
• Est. primary completion date: January 2005
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 35 Years to 69 Years

Eligibility

Inclusion Criteria:

• Patients diagnosed of fibromyalgia according to the American College of Rheumatology criteria for at least three years.

Exclusion Criteria:

• Orthopedic limitation, or cardiovascular, pulmonary, or metabolic disease that would preclude exercise.

• Participation in any other study.

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Fibromyalgia
• Hormonal Responses to Exercise in Patients With Fibromyalgia.
• Myofascial Pain Syndromes

Intervention

Device:
• Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands
Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
• Placebo Whole-body vibration exercise
Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.

Locations

Country	Name	City	State
Spain	Institut Nacional d'Educación Física de Catalunya	Barcelona

Sponsors (1)

Lead Sponsor	Collaborator
Institut Nacional d'Educacio Fisica de Catalunya

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum IGF-1 levels		Baseline, Week 1, Week 3, Week 6	Yes